Differential effects of the enantiomers R(−) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: Studies on depressed patients and normal controls

doi:10.1016/0924-977X(93)90263-L

European Neuropsychopharmacology

Volume 3, Issue 2, June 1993, Pages 117-126

https://doi.org/10.1016/0924-977X(93)90263-L Get rights and content

Abstract

The effects of the optically enantiomers of oxaprotiline (OXP), R(−) OXP and S(+) OXP, on depressive symptomatology and the sleep EEG were investigated in two separate exploratory studies. In addition, the neuroendocrine profile of both compounds was characterized in normal controls. In the patients treated with a daily oral dose of 150 mg S(+) OXP we found a Hamilton depression score that decreased from 29.1±1.8 (SEM) on day 0 to 14.7±3.2 on day 28 (P<0.01). Six patients were judged to be full responders (HAMD score 0–7 points), three were improved (HAMD score 8–15) and four were nonresponders (HAMD score > 16). The therapeutic effect achieved with 150 mg R(−) OXP daily was less pronounced: the HAMD score decreased from 27.8±2.5 on day 0 to 19.4±3.2 on day 28 (P<0.05). There were two full responders, one improved patient and even nonresponders. The sleep EEG scoring revealed a marked suppression of REM sleep among patients treated with S(+) OXP but not with R(−) OXP. In the normal controls, a single oral dose of 75 mg S(+) OXP promoted an increase in the secretion of cortisol and growth hormone, whereas 75 mg R(−) OXP did not. Neither enantiomer indluence the secretion of testosterone or prolactin.

References (34)

N. Matussek et al.
Effect of clonidine on growth hormone release in psychiatric patients and controls
Psychiatr. Res.
(1980)
R. Mishra et al.
Oxaprotiline: Induction of central noradrenergic subsensitivity by its (+)-enantiomer
Life Sci.
(1982)
P.M. Plotsky et al.
Neurotransmitter modulation of corticotropin releasing factor secretion into hypophysial-portal circulation
Life Sci.
(1987)
B. Szabo et al.
The noradrenaline uptake inhibitor, (+)-oxaprotiline, but not the inactive enantiomer, (−)-oxaprotiline, inhibits sympathetic nerve activity in the rabbit: Involvement of adrenoceptors
Eur. J. Pharmacol.
(1991)
P.C. Waldmeier et al.
Selective inhibition of noradrenaline and serotonin uptake by C 49802 and CGP 6085 A
Eur. J. Pharmacol.
(1977)
P.C. Waldmeier et al.
Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer
Biochem. Pharmacol.
(1982)
Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMDP)
(1979)
P. Bech et al.
The Melancholia Scale: Development, consistency, validity and utility
A.T. Beck et al.
An inventory for measuring depression
Arch. Gen. Psychiatry
(1961)
S.A. Checkley et al.
Clinical studies of the effect of (+) and (−)-oxaprotiline upon noradrenaline uptake
Psychopharmacology
(1985)

A. Delini-Stula et al.

Stereospecificity of behavioral and biochemical responses to oxaprotiline - a new antidepressant

Adv. Biochem. Psychopharmacol.

(1982)

J.M. Gaillard

Sommeil et psychotropes

J. Pharmacol. (Paris)

(1984)

M. Hamilton

A rating scale for depression

J. Neurol. Neurosurg. Psychiatry

(1960)

M. Hamilton

Hamilton Anxiety Scale

G. Laakmann et al.

Stimulation of growth hormone secretion by desimipramine and chlorimipramine in man

J. Clin. Endocrinol. Metab.

(1977)

J. Maj et al.

(+)-Oxaprotiline but not (−)-oxaprotiline given chronically potentiates the aggressive behaviour induced by clonidine

J. Pharm. Pharmacol.

(1983)

J. Maj et al.

Pharmacological effects of oxaprotiline enantiomers on the central serotonin system

Pol. J. Pharmacol. Pharm.

(1989)

Cited by (14)

Neuroscience-driven discovery and development of sleep therapeutics
2014, Pharmacology and Therapeutics
Citation Excerpt :
In patients with depression S(+)oxaprotiline, but not R(−)oxaprotiline suppressed REM sleep. The antidepressive effects of S(+)oxaprotiline were superior to those of R(−)oxaprotiline (Steiger et al., 1993a) and only S(+)oxaprotiline was endocrinologically active as it stimulates GH. As discussed above GH stimulants have sleep promoting properties.
Until recently, neuroscience has given sleep research and discovery of better treatments of sleep disturbances little attention, despite the fact that disturbed sleep has overwhelming impact on human health. Sleep is a complex phenomenon in which specific psychological, electrophysiological, neurochemical, endocrinological, immunological and genetic factors are involved. The brain as both the generator and main object of sleep is obviously of particular interest, which makes a neuroscience-driven view the most promising approach to evaluate clinical implications and applications of sleep research. Polysomnography as the gold standard of sleep research, complemented by brain imaging, neuroendocrine testing, genomics and other laboratory measures can help to create composite biomarkers that allow maximizing the effects of individualized therapies while minimizing adverse effects. Here we review the current state of the neuroscience of sleep, sleep disorders and sleep therapeutics and will give some leads to promote the discovery and development of sleep medicines that are better than those we have today.
Wake and sleep EEG provide biomarkers in depression
2010, Journal of Psychiatric Research
Citation Excerpt :
S(+)oxaprotiline, but not R(−)oxaprotiline suppressed REM sleep in patients with depression. S(+)oxaprotiline was superior to R(−)oxaprotiline in its antidepressive effects (Steiger et al., 1993a). Whereas the effects of the vast majority of antidepressants on REM sleep are similar, there exist differences in their influence on sleep continuity and on nonREM sleep.
Both wake and sleep electroencephalogram (EEG) provide biomarkers of depression and antidepressive therapy, respectively. For a long time it is known that EEG activity is altered by drugs. Quantitative EEG analysis helps to delineate effects of antidepressants on brain activity. Cordance is an EEG measure with a superior correlation with regional brain perfusion. Prefrontal quantitative EEG cordance appears to be a predictor of the response to antidepressants. Sleep EEG shows characteristic changes in depression as impaired sleep continuity, desinhibition of REM sleep and changes of nonREM sleep. Elevated REM density (a measure for frequency of rapid eye movements) characterizes an endophenotype in family studies of depression. REM-sleep changes including a more distinct REM rebound after sleep deprivation are found in animal models of depression. Most antidepressants suppress REM sleep in depressed patients, normal controls and laboratory animals. REM suppression appears to be a distinct, but not an absolute requirement for antidepressive effects of a compound. Sleep-EEG variables like REM latency or certain clusters of variables were shown to predict the response to the treatment with a certain antidepressant or even the course of the disorder for several years. Some of these predictive sleep-EEG markers of the longterm course of depression appear to be closely related to hypothalamo-pituitary-adrenocortical system activity.
Glucocorticoids and depression
1999, Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism
Depression has been associated with impaired mineralocorticoid receptor function, restrained glucocorticoid receptor feedback at the level of the hypothalamic–pituitary–adrenal (HPA) axis, raised cortisol level and increased corticotropin-releasing factor activity, which may act in concert to induce the signs and symptoms of the disorder. Pre-clinical and clinical evidence suggests that both genetic and environmental factors contribute to the development of these HPA axis abnormalities in depressed patients. Support for this view derives from models using genetically modified animals and/or chronic stress exposure at different developmental stages, although all of the current approaches have to be viewed within their limitations to model the disease. However, both animal and human studies challenging the HPA system show at least some neuroendocrine and behavioural changes comparable to those seen in depression, suggesting that some of the depressive symptoms can be attributed to HPA axis hyperactivity. Moreover, normalization of the neuroendocrine function following chronic antidepressant drug treatment seems to be a prerequisite for stable remission of depressive psychopathology, i.e. that normalization of HPA function is critical for relief of the clinical symptomatology of this disorder.
Treatment of Sleep Disorders in Specific Psychiatric Diseases
2022, NeuroPsychopharmacotherapy
Depression and sleep
2019, International Journal of Molecular Sciences
REM sleep in patients with depression
2011, Rapid Eye Movement Sleep: Regulation and Function

View all citing articles on Scopus

^∗: Present address: Max Planck Institute of Psychiatry, Clinical Institute, Department of Psychiatry, Munich, Germany.

View full text

Differential effects of the enantiomers R(−) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: Studies on depressed patients and normal controls

Abstract

Psychiatr. Res.

Life Sci.

Life Sci.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Biochem. Pharmacol.

Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMDP)

The Melancholia Scale: Development, consistency, validity and utility

An inventory for measuring depression

Arch. Gen. Psychiatry

Clinical studies of the effect of (+) and (−)-oxaprotiline upon noradrenaline uptake

Psychopharmacology